Advaxis, Inc. Receives Patent In Japan For ADXS-HPV For The Treatment Of Cervical Cancer
3/18/2014 9:15:30 AM
PRINCETON, N.J., March 18, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.
Help employers find you! Check out all the jobs and post your resume.
comments powered by